NJ Weight Loss & Preventive Care

BPC-157

Patient Education Guide — What It Does, Why a Physician Would Prescribe It, and What the Evidence Says

NJ Weight Loss & Preventive Care Clinics PA
Physician's Offices: 420 Route 46 East Fairfield NJ 07004 & 1605 E Evesham Road Voorhees NJ 08043
(908) 598-0509  |  Jbock@njweightloss.us

📄 Download printable PDF This guide, print-ready 8.5×11 · works offline · save or share

← Back to the full Peptide Guide overview

Important Disclaimer — Read Before Using This Page

This information is not intended for use by unlicensed individuals or by licensed professionals who lack adequate training and experience in assessing patients for peptide or hormone therapy. All clinical decisions and dosing must be made in consultation with a licensed, experienced physician and a licensed, experienced compounding pharmacist, and should be supported by published clinical studies.

The information presented here has been compiled using Artificial Intelligence, statements from videos and websites by apparent qualified professionals, and available published research. We strongly encourage exhaustive independent research before considering any therapy. Anyone starting a medication they have never taken before should take an extremely conservative approach.

Nothing on this page or in these videos should be taken as medical advice. These materials are provided only to help begin your research. All dosing and treatment decisions should be made between you and your medical providers after proper evaluation. We are not affiliated with any of the doctors whose videos appear on this page.

BPC-157 Compounded

Category: Tissue Repair & Recovery

How it works. BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. The proposed mechanisms include stimulation of angiogenesis (new blood vessel formation), fibroblast migration, nitric oxide modulation, growth-factor signaling enhancement, and anti-inflammatory effects. In animal and cell-culture work, it also shifts macrophage activity from pro-inflammatory (M1) to reparative (M2) phenotypes. It has been marketed for tendon, ligament, muscle, nerve, bone, gut mucosal, and wound healing.

Why a physician might discuss it, and where the evidence actually is. Patients love BPC-157 because they are injured, they want to avoid surgery, and they have read remarkable recovery stories online. Physicians should be more measured, because the published evidence base is overwhelmingly preclinical—animal studies, cell-culture work, and theoretical reviews, predominantly from Croatian and Japanese research groups. No controlled human efficacy trial in any indication has reached FDA approval status. One small human pharmacokinetic study exists, which tells us something about absorption but nothing about whether the compound heals human tendons or repairs human gut lining. That is the honest state of the evidence.

Patient selection and cautions. BPC-157 is most defensibly discussed for stubborn soft-tissue injuries after standard evaluation and conservative management have been tried—an MRI-documented rotator cuff strain that has failed physical therapy, for example, is a more defensible indication than vague "I want to feel better." It is not a substitute for imaging, physical therapy, or surgical evaluation when those are indicated. Theoretical angiogenesis concerns matter in any patient with active or recent cancer or proliferative disease. FDA compounding status has been actively contested and can shift between quarters—your prescriber should verify current pharmacy availability before every prescription.

Published Evidence: Animal studies suggest BPC-157 promotes tendon, ligament, muscle, nerve, and bone healing through upregulation of growth factors (VEGF, FGF) and anti-inflammatory cytokine modulation. A 2021 retrospective study (Lee & Padgett) of 16 patients receiving intra-articular BPC-157 (alone or with TB4) reported 87.5% (14/16) achieving significant pain relief at 6–12 months. A 2024 pilot in 12 patients with interstitial cystitis reported 80–100% resolution after intravesicular BPC-157. A 2025 pilot of 2 healthy adults receiving IV BPC-157 up to 20 mg showed excellent tolerability with no adverse events. These are early human signals, not definitive efficacy trials.
Key Studies:
• Lee & Padgett. "BPC-157 and TB4 for knee pain." Retrospective study, 2021.
• Lee et al. "Intravesicular BPC-157 for interstitial cystitis." Pilot study, 2024.
• Lee & Burgess. "IV BPC-157 safety in healthy adults." Pilot study, 2025.

Recommended Videos

BPC-157: Everything You Need to Know — Benefits, Risks, Dosing, & Delivery Methods

Quinn Stillson, MD — BPC-157: Everything You Need to Know — Benefits, Risks, Dosing, & Delivery Methods

Origins & Effects of BPC-157

Dr. Abud Bakri & Dr. Andrew Huberman — Huberman Lab Clips — Origins & Effects of BPC-157

Peptide BPC-157 — Does It Work? Breaking Down the Evidence and the Hype

Talking With Docs — Peptide BPC-157 — Does It Work? Breaking Down the Evidence and the Hype

Video Sources & Independence

The videos linked on this page are provided solely for educational purposes. None of the physicians or channels featured are sponsored by, affiliated with, or compensated by NJ Weight Loss & Preventive Care Clinics, its physicians, or any individuals associated with our practice. We have selected these videos because they offer thoughtful, evidence-based discussion of mechanisms and clinical considerations. Viewers should evaluate all sources independently.

← Back to the full Peptide Guide overview  ·  Peptide Dosing Reference →